PALO ALTO, Calif., June 30, 2014 (GLOBE NEWSWIRE) -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, today announced the presentation of Phase 1 data on the safety and tolerability of its lead compound NT100, a novel rhG-CSF being developed for use in repeat implantation failure and recurrent miscarriage. The data will be presented at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting to be held from June 29 to July 2 in Munich, Germany.
Help employers find you! Check out all the jobs and post your resume.
